by Damon Race | Sep 12, 2022 | In the News
By Zac Ezzone – Staff writer, Triangle Business Journal Sep 1, 2022 A UNC-Chapel Hill spinout developing gene therapies focused on rare blood diseases and disorders has raised $1.4 million to support its efforts. The company, GeneVentiv Therapeutics, raised the...
by Damon Race | Jun 14, 2022 | In the News
The Old Well on the UNC-Chapel Hill campus. Mehmet Demirci By Zac Ezzone – Staff writer June 14, 2022, 08:52am EDT After bootstrapping for nearly two years, the CEO of a UNC-Chapel Hill spinout developing gene therapies has received some financial support. In...
by Damon Race | Jun 8, 2022 | In the News
Pixabay image by Jason Parker — June 8, 2022 RALEIGH – GeneVentiv Therapeutics, a Triangle-area pre-clinical gene therapy company, has been awarded a $250,000 Strategic Research Loan (SRL) from the North Carolina Biotechnology Center (NCBC). The loan will enable the...
by Damon Race | Feb 8, 2022 | In the News
by Shellie Edge, Innovate Carolina — February 8, 2022 . Editor’s note: Startup Spotlight is a regular weekly feature in WRAL TechWire. This week’s feature comes from UNC-Chapel Hill’s Innovate Carolina. +++ CHAPEL HILL – For most people, a small cut on the hand or...
by Damon Race | Nov 2, 2021 | Press
Preclinical data provide quantitative evidence of GENV-HEM’s ability to achieve phenotypic correction in animal models of hemophilia, independent of the presence of any clotting factor inhibitors. Estimated 95,000 patients in the U.S. and Europe represent...
Recent Comments